Charles M. Rudin, MD, PhD, presenting LBA8505, Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). during L

Photo Galleries

Powered by SmugMug Owner Log In